Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.65

€1.65

-1.660%
-0.028
-1.660%
-
 
27.08.24 / Frankfurt WKN: A2DS5F / Name: Valbiotis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Financial data and news for Valbiotis

sharewise wants to provide you with the best news and tools for Valbiotis, so we directly link to the best financial data sources.

News

 Valbiotis invited to present clinical results at the American Diabetes Association’s 84th Scientific Sessions : https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis invited to present clinical results at the American Diabetes Association’s 84th Scientific Sessions
Valbiotis invited to present clinical results at the American Diabetes Association’s 84th Scientific Sessions
Valbiotis reaches an agreement to terminate its licensing  and supply agreement with Nestlé Health Science: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science
Valbiotis reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science
Valbiotis launches its e-commerce site  for the marketing of Valbiotis®PRO Cholestérol: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol
Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol
Valbiotis publishes its annual accounts 2023: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis publishes its annual accounts 2023
Valbiotis publishes its annual accounts 2023
Valbiotis to launch its 100% natural dietary supplement  for the management of hypercholesterolemia  on the French market in May: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May